skip to main content

Manufacturing Vaccines

The 2009 H1N1 flu pandemic underscored the need to update our national capabilities to provide timely access to domestically produced pandemic influenza vaccines.

The Center will be responsible for supplying the nation with 50 million doses of pandemic influenza vaccine within four months of notification of the influenza strain by government authorities and will utilize new flexible approaches and proprietary technologies from its partners to achieve this critical augmentation of domestic biomanufacturing capacity.

The Center is currently in discussions with potential Influenza Partners.

The Center has also developed manufacturing capabilities using varied platforms at large scale for use in preclinical, Phase I, and Phase II clinical trials. This capacity will allow scientists to accelerate their research to develop lifesaving vaccines.

Task Orders

Anthrax Vaccine

The Center for Innovation in Advanced Development and Manufacturing (CIADM) led by the Texas A&M University System will support development of a second-generation anthrax vaccine under a task order issued by the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR).

More details about this Task Order:

Last edited by: ebutton